Atezolizumab for PD-L1–High Non-Small Cell Lung Cancer: David Spigel, MD

Atezolizumab (Tecentriq®, Genentech, Inc.) was recently approved by the FDA for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high expression of programmed death ligand-1 (PD-L1). The approval was based on IMpower110, a phase 3 trial led by David Spigel, MD, Chief Scientific Officer and Director of the Lung Cancer Research Program at Sarah Cannon Research Institute in Nashville, Tennessee. In this interview with i3 Health, Dr. Spigel discusses the s...
Continue reading

FDA Approves Nivolumab/Ipilimumab/Platinum-Doublet Chemotherapy: NSCLC

Nivolumab (Opdivo®, Bristol Myers Squibb) plus ipilimumab (Yervoy®, Bristol Myers Squibb) in combination with 2 cycles of platinum-doublet chemotherapy has been FDA approved for treatment-naive patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Approval was based on the randomized, open-label trial CHECKMATE-9LA (NCT03215706). A total of 719 patients with met...
Continue reading

Atezolizumab Approved for PD-L1–High Non-Small Cell Lung Cancer

The FDA has expanded the approval of atezolizumab (Tecentriq®, Genentech, Inc.) to include adults with untreated metastatic non-small cell lung cancer (NSCLC) with high expression of programmed death ligand-1 (PD-L1). High PD-L1 expression is defined as PD-L1 staining on at least 50% of tumor cells or tumor-infiltrating immune cells covering at least 10% of the tumor area. In addition, the FDA has approved a companion diagnostic device, the Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, I...
Continue reading

Capmatinib Approved: Metastatic Non-Small Cell Lung Cancer

The FDA has granted accelerated approval to capmatinib (TabrectaTM, Novartis) for adults with metastatic non­-small cell lung cancer (NSCLC) with mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping. In addition, the FDA approved the FoundationOne® CDx (F1CDx) assay (Foundation Medicine, Inc.) as a companion diagnostic. Approval was based on the phase 2 GEOMETRY mono-1 trial (NCT02414139), a multicenter, nonrandomized trial evaluating capmatinib in patients with MET ex...
Continue reading

COVID-19 Risk in Cancer Patients: Melvin LK Chua, MBBS, FRCR, PhD, and Conghua Xie, MD, PhD

Last week, a research team under the direction of Conghua Xie, MD, PhD, and Melvin LK Chua, MBBS, FRCR, PhD, reported in JAMA Oncology that patients with cancer at a hospital in Wuhan, China, experienced an increased risk of COVID-19 infection relative to other members of the community. In this interview with i3 Health, Dr. Chua and Dr. Xie discuss their findings and analyze possible factors contributing to the increased risk of COVID-19 infection in patients with cancer. Can you comment on the ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.